Research and Markets (http://www.researchandmarkets.com/research/99f5fa/acute_coronary_syn)
has announced the addition of GlobalData's new report "Acute
Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016"
to their offering.
“Acute
Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016”
Acute
Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Acute
Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
provides key data, information and analysis on the global acute coronary
syndrome disease market. The report provides a comprehensive overview of
the annualized market data from 2001 to 2009, and forecasts for seven
years to 2016. The report provides coverage of the market landscape,
market drivers and restraints, and an in-depth pipeline analysis. The
current competitive landscape is also analyzed and the unmet need or
commercial opportunity of the market is calculated. The pipeline
analysis covers molecules across all phases of clinical development and
provides an overview of the developing trends among pipeline molecules,
as well as an insight into the most promising pipeline drugs
supplemented with key company profiles. By considering the current
competition in the market and the prospects of the pipeline molecules,
the resulting implications for the future market competition is also
outlined.
The Acute Coronary Syndrome Market is Estimated to Shrink at a Compound
Annual Growth Rate (CAGR) of 1% from 2009 to 2016
The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in
2009 and is forecast to decline by 1% annually for the next seven years
to reach $949m in 2016. This decline in market size is primarily due to
the patent expirations of six branded drugs which will subsequently
allow the entry of generics.
Current Treatment Options Cater to Most of the Market Needs
At present the ACS market is competitive with six approved drugs. The
dominant class of drug is glycoprotein (GP) IIb/IIIa receptor
antagonist. Plavix is an ADP mediated GP IIb/IIIa receptor antagonist in
combination with aspirin and dominates the market. Lovenox which was
approved in 2007 dominates the Percutaneous Coronary Intervention (PCI)
treatment segment of the ACS market. The heavy intracranial bleeding and
abdominal bleeding associated with high doses of these anti coagulants
leaves a significant area of unmet need for a new entrant.
Opportunity and Unmet Need in the Acute Coronary Syndrome Market, 2010
Competitive Acute Coronary Syndrome Market Consists of Six Approved
Drugs and Off Label Usages
Sanofi-Aventis, GlaxoSmithKline (GSK), and Bristol-Myers Squibb, are the
leading competitors in the global ACS market. The competitive landscape
is moderately populated with six products, three of which can be
described as strong. This market is characterized by moderate levels of
off label usage.